

- 51 **Pekala PH**, Price SR, Horn CA, *et al.* Model for cachexia in chronic disease: secretory products of endotoxin-stimulated macrophages induce a catabolic state in 3T3-L1 adipocytes. *Trans Assoc Am Physicians* 1984;**97**:251–9.
- 52 **Doehner W**, Pflaum CD, Rauchhaus M, *et al.* Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. *Eur J Endocrinol* 2001;**145**:727–35.
- 53 **Morrison WL**, Gibson JN, Rennie MJ. Skeletal muscle and whole body protein turnover in cardiac cachexia: influence of branched-chain amino acid administration. *Eur J Clin Invest* 1988;**18**:648–54.
- 54 **Adigun AQ**, Ajayi AA. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. *Eur J Heart Failure* 2001;**3**:359–63.
- 55 **Karunaweera ND**, Grau GE, Gamage R, *et al.* Dynamics of fever and serum levels of tumor necrosis are closely associated during clinical paroxysms in *Plasmodium vivax* malaria. *Proc Natl Acad Sci USA* 1992;**89**:3200–3.
- 56 **Hotez PJ**, Le Trang N, Fairlamb AH, *et al.* Lipoprotein lipase suppression in 3T3-L1 cells by a haematoprotazoan-induced mediator from peritoneal exudate cells. *Parasite Immunol* 1984;**3**:203–9.
- 57 **Hirunpetcharot C**, Finkelman F, Clark IA, *et al.* Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease. *Parasite Immunol* 1999;**21**:319–29.
- 58 **Hensmann M**, Kwiatkowski D. Cellular basis of early cytokine response to *Plasmodium falciparum*. *Infect Immun* 2001;**69**:2364–71.
- 59 **Akanmori BD**, Kurtzhals JAL, Goka BQ, *et al.* Distinct patterns of cytokine regulation in discrete clinical forms of *Plasmodium falciparum* malaria. *Eur Cytokine Netw* 2000;**11**:13–18.
- 60 **Othoro C**, Laa AA, Nahlen B, *et al.* A low interleukin-10 tumor necrosis factor- $\alpha$  ratio is associated with malaria anaemia in children residing in holoendemic malaria region in Western Kenya. *J Infect Dis* 1999;**179**:279–82.
- 61 **Allan RJ**, Beattie P, Bate C, *et al.* Strain variation in tumor necrosis factor induction by parasites from children with acute *falciparum* malaria. *Infect Immun* 1995;**63**:1173–5.
- 62 **Singh S**, Singh N, Handa R. Tumor necrosis factor- $\alpha$  in patients with malaria. *Indian J Malariol* 2000;**37**:27–33.
- 63 **Migot-Nabias F**, Deloron P, Ringwald P, *et al.* Immune response to *Plasmodium falciparum* liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. *Trans R Soc Trop Med Hyg* 2000;**94**:557–62.
- 64 **Nussenblatt V**, Mukasa G, Metzger A, *et al.* Anaemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute uncomplicated *Plasmodium falciparum* malaria. *Clin Diagn Lab Immunol* 2001;**8**:1164–70.
- 65 **Jason J**, Archibald LK, Nwanyanwu OC, *et al.* Comparison of serum and cell-specific cytokines in humans. *Clin Diagn Lab Immunol* 2001;**8**:1097–103.
- 66 **Ferrari R**. The role of TNF in cardiovascular disease. *Pharmacol Res* 1999;**40**:97–105.
- 67 **Krown KA**, Page MT, Nguyen C, *et al.* Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. *J Clin Invest* 1996;**98**:2854–65.
- 68 **Kurtzhals JAL**, Adabayeri V, Goka BQ, *et al.* Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. *Lancet* 1998;**351**:1768–72.
- 69 **Cicoira M**, Bolger AP, Doehner W, *et al.* High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. *Cytokine* 2001;**15**:80–6.
- 70 **Wattavidanage J**, Carter R, Perera KL, *et al.* TNF- $\alpha$ 2 marks high risk of severe disease during *Plasmodium falciparum* malaria and other infections in Sri Lankans. *Clin Exp Immunol* 1999;**115**:350–5.
- 71 **Modiano D**, Petrarca V, Sirima BS, *et al.* Different response to *Plasmodium falciparum* malaria in west African sympatric ethnic groups. *Proc Natl Acad Sci USA* 1996;**93**:13206–11.
- 72 **Anker SD**, Negassa A, Coats AJS, *et al.* Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. *Lancet* 2003;**361**:1077–83.
- 73 **Coats AJS**, Adamopoulos S, Meyer TE, *et al.* Effects of physical training in chronic heart failure. *Lancet* 1990;**335**:63–6.
- 74 **Mc Namara DM**, Holubkov R, Starling RC, *et al.* Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. *Circulation* 2001;**103**:2254–9.
- 75 **Feingold KR**, Serio MJ, Adi S, *et al.* Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. *Endocrinology* 1989;**24**:2336–42.
- 76 **Mohanty S**, Mishra SK, Das BS, *et al.* Altered plasma lipid pattern in *falciparum* malaria. *Ann Trop Med Parasitol* 1992;**86**:601–6.
- 77 **Drexler H**, Hornig BD. Endothelial dysfunction in human disease. *J Mol Cell Cardiol* 1999;**31**:51–60.
- 78 **Sein KK**, Aikawa M. The prime role of plasma membrane cholesterol in the pathogenesis of immune evasion and clinical manifestations of *falciparum* malaria. *Med Hypotheses* 1998;**51**:105–10.
- 79 **Kjekshus J**. Debate: statins should be used in patients with heart failure. *Curr Control Trials Cardiovasc Med* 2001;**2**:268–70.
- 80 **Rauchhaus M**, Koloczek V, Volk HD, *et al.* Inflammatory cytokines and possible immunological role for lipoproteins in chronic heart failure. *Int J Cardiol* 2000;**76**:125–33.
- 81 **Barnes PJ**. Therapeutic strategies for allergic diseases. *Nature* 2000;**402**:B31–8.
- 82 **Barnes PJ**. Cytokine modulators as novel therapies for asthma. *Annu Rev Pharmacol Toxicol* 2002;**42**:81–98.
- 83 **Di Perri G**, Di Perri IG, Monteiro GB, *et al.* Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. *J Infect Dis* 1995;**171**:1317–22.
- 84 **Skudicky D**, Bergmann A, Silva K, *et al.* Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. *Circulation* 2001;**103**:1083–8.
- 85 **Bozkurt B**, Villaneuva FS, Holubkov R, *et al.* Intravenous immune globulin in the therapy of peripartum cardiomyopathy. *J Am Coll Cardiol* 1999;**34**:177–80.
- 86 **Sabchareon A**, Burnouf T, Ouattara D, *et al.* Parasitologic and clinical response to immunoglobulin administration in *falciparum* malaria. *Am J Trop Med Hyg* 1991;**45**:297–308.
- 87 **Gullestad L**, Aass H, Fjeld JG, *et al.* Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. *Circulation* 2001;**103**:220–5.
- 88 **Kikafunda JK**, Walker AF, Collett D, *et al.* Risk factors for early childhood malnutrition in Uganda. *Pediatrics* 1998;**102**:e45.
- 89 **Nacher M**, Singhasivanon P, Vannaphan S, *et al.* Socio-economic and environmental protective/risk factors in severe malaria in Thailand. *Acta Trop* 2001;**78**:139–46.

## CORRECTION

doi: 10.1136/pgmj.2004.019356corr1

An error occurred in the paper “Chorea and related disorders” by Bhidayasiri and Truong published in the September issue (*Postgrad Med J* 2004;**80**:527–34). On page 528, “Box 1: Clinical features of Huntington’s disease”, the 8th bullet point should read “No curative treatment; symptomatic treatment with dopamine antagonists”.